2025 · 4th Quarter (Oct 1 - Dec 31)

NOVO NORDISK, INC.

Filed by ARNOLD & PORTER KAYE SCHOLER LLP.

Open official filing

Source-reported fields

Filing overview

Type: 4th Quarter - Report
Posted: Jan 14, 2026
Income: $70,000.00
Expenses: Not reported
Registrant: ARNOLD & PORTER KAYE SCHOLER LLP
Client: NOVO NORDISK, INC.
Filing UUID: 594f84d7-26f0-46a1-901f-e569db8dce6c
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

PHA · Pharmacy

Issues related to general compounding.

HCR · Health Issues

Issues related to the clinical and overall benefit of anti-obesity medications. Issues related to insulin pricing/affordability. Issues related to general compounding.

MMM · Medicare/Medicaid

Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2025 (H.R. 4231 / S. 1973).

Literal federal measure citations: H.R. 4231, S. 1973

CSP · Consumer Issues/Safety/Products

Issues related to general compounding.

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.